Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12013MR)

This product GTTS-WQ12013MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12013MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14851MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ2348MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ10396MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ8015MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ7850MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ13489MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ15838MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ1377MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-874
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW